Applying probiotics and prebiotics in new delivery formats – is the clinical evidence transferable?

Autores
Cunningham, Marla; Vinderola, Celso Gabriel; Charalampopoulos, Dimitris; Lebeer, Sarah; Sanders, Mary Ellen; Grimaldi, Roberta
Año de publicación
2021
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Background: There is substantial demand for gut health products incorporating probiotics and prebiotics. They are being delivered as ingredients in an increasing range of different product formulations. While new delivery matrices are assessed for their potential impact on cell viability and prebiotic degradation, it is unknown whether they should be expected to independently alter the clinical effect of a given probiotic and prebiotic. Scope and approach: We provide an overview of preclinical and clinical data to examine the degree to which probiotic and prebiotic efficacy may be altered by processing and incorporation into various delivery matrices. We also consider the impact of inter-individual host factors on product efficacy. We further review regulatory positions across the globe on substantiation of prebiotic and probiotic efficacy in the final product format. Key findings and conclusions: In vitro data suggest that the delivery matrix may interact with prebiotic and probiotic functions via various physicochemical interactions with molecular and cellular structures and changes in cellular expression. However, direct evidence to suggest these changes have a significant in vivo impact is very limited. Indeed, meta-analyses suggest a robustness of effect across delivery matrices. Regulatory expectations vary among regions, but scope typically exists for adequate scientific justification to translate probiotic or prebiotic evidence across product formats. Early evidence suggests host factors such as diet, health and microbiome status are likely to play an important role in an individual´s response to a given probiotic and prebiotic.
Fil: Cunningham, Marla. No especifíca;
Fil: Vinderola, Celso Gabriel. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Santa Fe. Instituto de Lactología Industrial. Universidad Nacional del Litoral. Facultad de Ingeniería Química. Instituto de Lactología Industrial; Argentina
Fil: Charalampopoulos, Dimitris. University of Reading; Reino Unido
Fil: Lebeer, Sarah. Universiteit Antwerp; Bélgica
Fil: Sanders, Mary Ellen. International Scientific Association For Probiotics And Prebiotics; Estados Unidos
Fil: Grimaldi, Roberta. No especifíca;
Materia
DELIVERY MATRIX
HOST FACTORS
PREBIOTIC
PROBIOTIC
PRODUCT FORMULATION
REGULATORY
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/157469

id CONICETDig_d9b7d4e88f4e325b56efb39b618f1032
oai_identifier_str oai:ri.conicet.gov.ar:11336/157469
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Applying probiotics and prebiotics in new delivery formats – is the clinical evidence transferable?Cunningham, MarlaVinderola, Celso GabrielCharalampopoulos, DimitrisLebeer, SarahSanders, Mary EllenGrimaldi, RobertaDELIVERY MATRIXHOST FACTORSPREBIOTICPROBIOTICPRODUCT FORMULATIONREGULATORYhttps://purl.org/becyt/ford/2.11https://purl.org/becyt/ford/2Background: There is substantial demand for gut health products incorporating probiotics and prebiotics. They are being delivered as ingredients in an increasing range of different product formulations. While new delivery matrices are assessed for their potential impact on cell viability and prebiotic degradation, it is unknown whether they should be expected to independently alter the clinical effect of a given probiotic and prebiotic. Scope and approach: We provide an overview of preclinical and clinical data to examine the degree to which probiotic and prebiotic efficacy may be altered by processing and incorporation into various delivery matrices. We also consider the impact of inter-individual host factors on product efficacy. We further review regulatory positions across the globe on substantiation of prebiotic and probiotic efficacy in the final product format. Key findings and conclusions: In vitro data suggest that the delivery matrix may interact with prebiotic and probiotic functions via various physicochemical interactions with molecular and cellular structures and changes in cellular expression. However, direct evidence to suggest these changes have a significant in vivo impact is very limited. Indeed, meta-analyses suggest a robustness of effect across delivery matrices. Regulatory expectations vary among regions, but scope typically exists for adequate scientific justification to translate probiotic or prebiotic evidence across product formats. Early evidence suggests host factors such as diet, health and microbiome status are likely to play an important role in an individual´s response to a given probiotic and prebiotic.Fil: Cunningham, Marla. No especifíca;Fil: Vinderola, Celso Gabriel. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Santa Fe. Instituto de Lactología Industrial. Universidad Nacional del Litoral. Facultad de Ingeniería Química. Instituto de Lactología Industrial; ArgentinaFil: Charalampopoulos, Dimitris. University of Reading; Reino UnidoFil: Lebeer, Sarah. Universiteit Antwerp; BélgicaFil: Sanders, Mary Ellen. International Scientific Association For Probiotics And Prebiotics; Estados UnidosFil: Grimaldi, Roberta. No especifíca;Elsevier Science London2021info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/157469Cunningham, Marla; Vinderola, Celso Gabriel; Charalampopoulos, Dimitris; Lebeer, Sarah; Sanders, Mary Ellen; et al.; Applying probiotics and prebiotics in new delivery formats – is the clinical evidence transferable?; Elsevier Science London; Trends In Food Science & Technology (regular Ed.); 112; 2021; 495-5060924-2244CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.1016/j.tifs.2021.04.009info:eu-repo/semantics/altIdentifier/url/https://www.sciencedirect.com/science/article/pii/S0924224421002612?via%3Dihubinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-nd/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-10T13:03:09Zoai:ri.conicet.gov.ar:11336/157469instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-10 13:03:09.724CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Applying probiotics and prebiotics in new delivery formats – is the clinical evidence transferable?
title Applying probiotics and prebiotics in new delivery formats – is the clinical evidence transferable?
spellingShingle Applying probiotics and prebiotics in new delivery formats – is the clinical evidence transferable?
Cunningham, Marla
DELIVERY MATRIX
HOST FACTORS
PREBIOTIC
PROBIOTIC
PRODUCT FORMULATION
REGULATORY
title_short Applying probiotics and prebiotics in new delivery formats – is the clinical evidence transferable?
title_full Applying probiotics and prebiotics in new delivery formats – is the clinical evidence transferable?
title_fullStr Applying probiotics and prebiotics in new delivery formats – is the clinical evidence transferable?
title_full_unstemmed Applying probiotics and prebiotics in new delivery formats – is the clinical evidence transferable?
title_sort Applying probiotics and prebiotics in new delivery formats – is the clinical evidence transferable?
dc.creator.none.fl_str_mv Cunningham, Marla
Vinderola, Celso Gabriel
Charalampopoulos, Dimitris
Lebeer, Sarah
Sanders, Mary Ellen
Grimaldi, Roberta
author Cunningham, Marla
author_facet Cunningham, Marla
Vinderola, Celso Gabriel
Charalampopoulos, Dimitris
Lebeer, Sarah
Sanders, Mary Ellen
Grimaldi, Roberta
author_role author
author2 Vinderola, Celso Gabriel
Charalampopoulos, Dimitris
Lebeer, Sarah
Sanders, Mary Ellen
Grimaldi, Roberta
author2_role author
author
author
author
author
dc.subject.none.fl_str_mv DELIVERY MATRIX
HOST FACTORS
PREBIOTIC
PROBIOTIC
PRODUCT FORMULATION
REGULATORY
topic DELIVERY MATRIX
HOST FACTORS
PREBIOTIC
PROBIOTIC
PRODUCT FORMULATION
REGULATORY
purl_subject.fl_str_mv https://purl.org/becyt/ford/2.11
https://purl.org/becyt/ford/2
dc.description.none.fl_txt_mv Background: There is substantial demand for gut health products incorporating probiotics and prebiotics. They are being delivered as ingredients in an increasing range of different product formulations. While new delivery matrices are assessed for their potential impact on cell viability and prebiotic degradation, it is unknown whether they should be expected to independently alter the clinical effect of a given probiotic and prebiotic. Scope and approach: We provide an overview of preclinical and clinical data to examine the degree to which probiotic and prebiotic efficacy may be altered by processing and incorporation into various delivery matrices. We also consider the impact of inter-individual host factors on product efficacy. We further review regulatory positions across the globe on substantiation of prebiotic and probiotic efficacy in the final product format. Key findings and conclusions: In vitro data suggest that the delivery matrix may interact with prebiotic and probiotic functions via various physicochemical interactions with molecular and cellular structures and changes in cellular expression. However, direct evidence to suggest these changes have a significant in vivo impact is very limited. Indeed, meta-analyses suggest a robustness of effect across delivery matrices. Regulatory expectations vary among regions, but scope typically exists for adequate scientific justification to translate probiotic or prebiotic evidence across product formats. Early evidence suggests host factors such as diet, health and microbiome status are likely to play an important role in an individual´s response to a given probiotic and prebiotic.
Fil: Cunningham, Marla. No especifíca;
Fil: Vinderola, Celso Gabriel. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Santa Fe. Instituto de Lactología Industrial. Universidad Nacional del Litoral. Facultad de Ingeniería Química. Instituto de Lactología Industrial; Argentina
Fil: Charalampopoulos, Dimitris. University of Reading; Reino Unido
Fil: Lebeer, Sarah. Universiteit Antwerp; Bélgica
Fil: Sanders, Mary Ellen. International Scientific Association For Probiotics And Prebiotics; Estados Unidos
Fil: Grimaldi, Roberta. No especifíca;
description Background: There is substantial demand for gut health products incorporating probiotics and prebiotics. They are being delivered as ingredients in an increasing range of different product formulations. While new delivery matrices are assessed for their potential impact on cell viability and prebiotic degradation, it is unknown whether they should be expected to independently alter the clinical effect of a given probiotic and prebiotic. Scope and approach: We provide an overview of preclinical and clinical data to examine the degree to which probiotic and prebiotic efficacy may be altered by processing and incorporation into various delivery matrices. We also consider the impact of inter-individual host factors on product efficacy. We further review regulatory positions across the globe on substantiation of prebiotic and probiotic efficacy in the final product format. Key findings and conclusions: In vitro data suggest that the delivery matrix may interact with prebiotic and probiotic functions via various physicochemical interactions with molecular and cellular structures and changes in cellular expression. However, direct evidence to suggest these changes have a significant in vivo impact is very limited. Indeed, meta-analyses suggest a robustness of effect across delivery matrices. Regulatory expectations vary among regions, but scope typically exists for adequate scientific justification to translate probiotic or prebiotic evidence across product formats. Early evidence suggests host factors such as diet, health and microbiome status are likely to play an important role in an individual´s response to a given probiotic and prebiotic.
publishDate 2021
dc.date.none.fl_str_mv 2021
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/157469
Cunningham, Marla; Vinderola, Celso Gabriel; Charalampopoulos, Dimitris; Lebeer, Sarah; Sanders, Mary Ellen; et al.; Applying probiotics and prebiotics in new delivery formats – is the clinical evidence transferable?; Elsevier Science London; Trends In Food Science & Technology (regular Ed.); 112; 2021; 495-506
0924-2244
CONICET Digital
CONICET
url http://hdl.handle.net/11336/157469
identifier_str_mv Cunningham, Marla; Vinderola, Celso Gabriel; Charalampopoulos, Dimitris; Lebeer, Sarah; Sanders, Mary Ellen; et al.; Applying probiotics and prebiotics in new delivery formats – is the clinical evidence transferable?; Elsevier Science London; Trends In Food Science & Technology (regular Ed.); 112; 2021; 495-506
0924-2244
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.1016/j.tifs.2021.04.009
info:eu-repo/semantics/altIdentifier/url/https://www.sciencedirect.com/science/article/pii/S0924224421002612?via%3Dihub
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Elsevier Science London
publisher.none.fl_str_mv Elsevier Science London
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842980064312950784
score 12.993085